Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
2(20%)
Results Posted
57%(4 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_2
2
20%
Ph phase_1
1
10%
Ph not_applicable
1
10%
Ph phase_3
1
10%
Ph phase_4
5
50%

Phase Distribution

1

Early Stage

2

Mid Stage

6

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
2(20.0%)
Phase 3Large-scale testing
1(10.0%)
Phase 4Post-market surveillance
5(50.0%)
N/ANon-phased studies
1(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

2

trials recruiting

Total Trials

10

all time

Status Distribution
Active(2)
Completed(7)
Terminated(1)

Detailed Status

Completed7
Active, not recruiting1
Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
2
Success Rate
87.5%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (10.0%)
Phase 22 (20.0%)
Phase 31 (10.0%)
Phase 45 (50.0%)
N/A1 (10.0%)

Trials by Status

active_not_recruiting110%
terminated110%
completed770%
recruiting110%

Recent Activity

Clinical Trials (10)

Drug Details

Intervention Type
DRUG
Total Trials
10